Why Did Bausch + Lomb Stock Plunge 11.52%?

On April 30, 2025, Bausch + Lomb's stock experienced a significant drop of 11.52% in pre-market trading, reflecting a notable decline in investor sentiment.

Bausch + Lomb Corporation reported a net loss of $212 million for the first quarter of 2025, compared to $167 million in the same period last year. This increase in net loss has raised concerns among investors about the company's financial health and operational efficiency.

Despite the financial setbacks, Bausch + Lomb remains one of the largest vision care companies in the United States. The company operates in three key segments: vision care, surgical, and ophthalmic pharmaceuticals. Its vision care segment, which includes contact lenses and ocular health products, is a significant contributor to its market presence.

Analysts had anticipated earnings of $0.06 per share and revenue of $1.15 billion for the quarter. However, the actual revenue reported was $1.137 billion, slightly below expectations. This discrepancy has further contributed to the stock's decline, as investors reassess the company's growth prospects and financial stability.